Chinese ride-hailing platform DiDi swung to a loss attributable to shareholders of 1.22 billion yuan in the first quarter from the year-ago attributable profit of 2.36 billion yuan, according to the company's press release published Tuesday.
Loss per share for the period was 1.05 yuan against the earnings per share of 1.92 yuan a year earlier.
Revenue rose 10% year on year to 58.7 billion yuan from 53.3 billion yuan.
Sichuan Yahua Industrial (SHE:002497) directors approved the company's application for a designated delivery warehouse for lithium hydroxide by the Guangzhou Futures Exchange.The application will help the company organically combine the spot and futures markets and the delivery warehouse, according to a Wednesday disclosure to the Shanghai bourse.
A study showed that China has been owning over 11,300 patents developed in Germany for more than twenty years, Reuters reported Tuesday, citing a study from the German Economic Institute.A foreign entity owns almost one in three German-made inventions, with U.S. owners owning a third and Swiss owners holding about 11%, according to the Bertelsmann Foundation-commissioned study, the report said.China has been particularly active in acquiring technologies in mechanical engineering, where patent applications increased to 4,300 in 2022 from 3,300 in 2000, according to the media outlet.IW expert Oliver Koppel said Europe must make a deeper study on where these technologies are migrating due to the imbalance in Western acquisitions. He also said that Germany's insufficient investment in research and development is putting its domestic innovative capability in a fragile state, the report said.The report said Germany's R&D spending fell to the sixth spot globally in 2021 from the third place in 2000, while China raised its R&D investment twentyfold over the period, according to Reuters.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Lupin (NSE:LUPIN, BOM:500257) and its alliance partner Natco Pharma (NSE:NATCOPHARM, BOM:524816) said the US Food and Drug Administration has approved Eribulin Mesylate injection, 1 mg/2 mL, according to a filing.The drug is a generic version of Eisai Inc.'s reference drug Halaven, the filing said. It is used for the treatment of metastatic breast cancer in patients who have received prior chemotherapy and for unresectable or metastatic liposarcoma.Halaven recorded estimated annual US sales of $43.7 million, based on IQVIA MAT April 2026 data, it added.Shares of Natco Pharma fell over 1% in Wednesday's trade.